Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Global Progressive Supranuclear Palsy (PSP) Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, and Collaboration - ResearchAndMarkets.com

Research and Markets
Posted on: 07 Mar 18

The "Progressive Supranuclear Palsy (PSP) Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments" report has been added to ResearchAndMarkets.com's offering.

The study analyzed that PSP therapeutics pipeline comprises approximately 14 drug candidates in different stages of development.

According to research findings, most of the drug candidates in PSP therapeutics pipeline are being developed as small molecule agents. Also, majority of the pipeline drug candidates are being developed using the oral route of administration.

Many companies are more focused on developing their drug candidate's as small molecule, since small molecule can easily pass through the blood brain barrier due to their low molecular weight and small size.

In April 2017, Biogen Inc. entered into an exclusive worldwide license agreement with Bristol-Myers Squibb Company to develop and commercialize BMS-986168, a Phase II investigational medicine for the treatment of Alzheimer's disease (AD) and PSP. Some of the key players developing drugs for the treatment of progressive supranuclear palsy include AbbVie Inc., Biogen Inc., Asceneuron SA, Alzprotect SAS and others.

Report Segmentation

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

Key Topics Covered

Chapter 1. Research Background

1.1 Research Objectives

1.2 Definition

1.3 Research Scope

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

4.1 Overview

4.2 Key Drivers

4.3 Key Barriers

4.4 Progressive Supranuclear Palsy Therapeutics Pipeline Analysis

Chapter 5. Progressive Supranuclear Palsy Therapeutics Pipeline Analysis by Phase (2017)

5.1 Phase II/III: Drug profiles

5.2 Phase II: Drug profiles

5.3 Phase I: Drug profiles

5.4 Pre-Clinical: Drug profiles

Chapter 6. Clinical Trials Analysis

6.1 Clinical Trials by Region for Progressive Supranuclear Palsy Therapeutics Pipeline

6.2 Clinical Trials by Trial Status for Progressive Supranuclear Palsy Therapeutics Pipeline

Chapter 7. Competitive Landscape

7.1 Key Players Benchmarking for Progressive Supranuclear Palsy Therapeutics Pipeline

7.2 SWOT Analysis of Progressive Supranuclear Palsy Therapeutics Pipeline

Chapter 8. Company Profiles

8.1 Business Overview

8.2 Product and Service Offerings

For more information about this report visit https://www.researchandmarkets.com/research/jljcng/global?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180307005733/en/

Business Wire
www.businesswire.com

Last updated on: 07/03/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.